Quarterly report · Q2

Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥115.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥58.4bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥112.6bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥55.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥34.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥16.6bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥36.3bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥17.6bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥37.3bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥17.5bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥38.1bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥18.3bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥23.4bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.0bn2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥24.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥25.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥11.6bn2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥26.0bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥12.5bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥461.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥377.7bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥115.8bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥345.2bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥291.3bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥331.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥284.5bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥135.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥100.2bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥26.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥25.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥28.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥18.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥15.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥14.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥34.472023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥16.192023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥35.442022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.582022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥34.452023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥16.182023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥35.422022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.572022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.3%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥754m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥754m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥125m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥42m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥21m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥6m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥674m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥6.9bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥215m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥101m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥1.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-09-30¥45.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-07-01 → 2023-09-30¥23.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-09-30¥44.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-07-01 → 2023-09-30¥22.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥622m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-09-30¥18.4bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-07-01 → 2023-09-30¥9.5bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-09-30¥32.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-07-01 → 2023-09-30¥16.9bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-09-30¥32.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-07-01 → 2023-09-30¥16.9bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥11m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥0
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-09-30¥7.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-07-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-07-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-07-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥4m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-07-01 → 2023-09-30¥945m
—segment totalrevenue2023-04-01 → 2023-09-30¥116.4bn
—segment totalrevenue2023-07-01 → 2023-09-30¥58.5bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥114.6bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥57.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.7bn
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥733m
—segment totalsegment profit2023-04-01 → 2023-09-30¥34.4bn
—segment totalsegment profit2023-07-01 → 2023-09-30¥16.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥2.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥701m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥231m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥8.4bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥2.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥445m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥179m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.5bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥634m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥14.0bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥13.7bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥347m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥185m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2022-07-01 → 2022-09-30¥22.3bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-09-30¥40.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2022-07-01 → 2022-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥664m
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-09-30¥30.2bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2022-07-01 → 2022-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥4m
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥2m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-09-30¥18.8bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-09-30¥18.5bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2022-07-01 → 2022-09-30¥8.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥304m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2022-07-01 → 2022-09-30¥865m
—segment totalrevenue2022-04-01 → 2022-09-30¥113.9bn
—segment totalrevenue2022-07-01 → 2022-09-30¥55.9bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥111.2bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥54.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥2.7bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥1.0bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥36.9bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥17.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 811
ItemContextValueUnit
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の4の7第1項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-11-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第24期第2四半期(自 2023年7月1日 至 2023年9月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)エムスリー株式会社
Company name in english cover pageFilingDateInstantM3, Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長  谷 村   格
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区赤坂一丁目11番44号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03(6229)8900(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)執行役員     大 場   啓 史
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区赤坂一丁目11番44号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03(6229)8900(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員     大 場   啓 史
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05425
Fund codeFilingDateInstant-
Security codeFilingDateInstant24130
Filer name in japaneseFilingDateInstant
Original text (Japanese)エムスリー株式会社
Filer name in englishFilingDateInstantM3, Inc.
Fund name in japaneseFilingDateInstant-
Fund name in englishFilingDateInstant-
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantIFRS
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant-
Current fiscal year start dateFilingDateInstant2023-04-01
Current period end dateFilingDateInstant2023-09-30
Type of current periodFilingDateInstantQ2
Current fiscal year end dateFilingDateInstant2024-03-31
Previous fiscal year start dateFilingDateInstant2022-04-01
Comparative period end dateFilingDateInstant2022-09-30
Previous fiscal year end dateFilingDateInstant2023-03-31
Next fiscal year start dateFilingDateInstant-
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant-
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant-
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所プライム市場
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)単元株式数100株

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass